Clinical Research Directory

Study population Eligible patients are adults that whom TAVI is indicated as therapy for severe aortic valve stenosis and will be assigned randomly in a 1:1 ratio to either continue or withdraw the beta-blockers medication. Furthermore, they should satisfy all eligibility criteria (inclusion and exclusion). Inclusion criteria * Adults ≥18 years old. * Patient with severe symptomatic aortic stenosis defined by mean aortic gradient \> 40 mmHg or/and peak jet velocity \> 4.0 m/s or/and aortic valve area (AVA) \< 1cm2 or/and AVA indexed to body surface area (BSA) of \<0.6 cm2/m2. * Patients are considered at high risk for mortality with conventional surgical aortic valve replacement as assessed by a Heart Team consisting of at least a cardiologist and surgeon. * Patients with anatomic characteristics suitable for TAVI based on the local Heart Team decision. * Patients receiving beta-blockers as a part of their indicated treatment plan. * Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up. * Patient has given written consent to participate in the trial. Exclusion criteria * A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, bivalirudin, clopidogrel, titanium, nickel, cobaltium, chromium, contrast media. * Patients with permanent pacemaker or defibrillator. * Ongoing infection, including active endocarditis. * Echocardiographic evidence of LV or LA thrombus. * The patient that has any contraindication for antithrombotic treatment. * Estimated life expectancy of less than 12 months. * Pregnancy and pre-perimenopause. * 2nd and 3rd degree atrioventricular (AV) block. * Bradycardia (\<50 beats per minute) at the electrocardiogram (ECG) on the screening/baseline visit. * Co-morbidity that excludes or significantly interferes with the follow-up visits. * Enrolment in another study that competes or interferes with this study.